Complete Genomics (GNOM) tacks on another 2.2% gain premarket after surging yesterday on news that the Mayo Clinic will outsource whole human genome sequencing to the company. Shares are now up 59% YTD, but still trade at only a third of their 52-week highs.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs